The Endocrine Society Responds To Recent Insulin Glargine (Lantus(R)) Study With Recommendations For Patients And Physicians
The Endocrine Society Responds To Recent Insulin Glargine (Lantus(R)) Study With Recommendations For Patients And Physicians
Five articles recently posted online in the medical journal Diabetologia studied the possible connection between the use of insulin glargine (Lantus®) and the development of cancer. While one of these studies suggested an increased risk of cancer, the other four did not come to the same conclusion. Taken together, the results of all these studies do not conclusively show that insulin glargine causes cancer or is otherwise harmful to a patient's overall health.